Affordability of High Cost Medicines with Significant Public Health Implications under Medicines Patent Protection System in China_Chinese Journal of Evidence-Based Medicine

Authors：

 SUNJing ¹ , ZHAOHong-yan ¹ , MALi-ping ¹ , DONGSi-ping ¹ , YANGTing-ting ¹ , YokeLing ² , PaulCowthrone ³ , CHENXi-ping ² , CHENYou-ding ³

1. Department of Health Hospital Management Research Institute, Beijing 100191, China;
2. The Beijing Office of Third World Network, Beijing 100600, China;
3. Beijing Office of Doctors without Borders, Beijing 100600, China;

Corresponding author：

Keywords：

Medicines patent protection; Direct economic burden; Affordability

DOI：

10.7507/1672-2531.20140088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To propose policy recommendations for improvement of the affordability of high cost medicines with significant public health implications under the patent system in China. Methods Through literature analysis and market investigation, this study targeted expensive life saving medicines under the patent protection, which are critical for the treatment of eight diseases with the most significant disease burden and critical social, economic and political impact for case studies, estimated the individual and insurance direct economic burden of medicines treatment. Results Chemical product patent protection enhanced medicines price monopoly. The targeted medicines brought huge financial burden to Chinese citizens, especially to the rural residents. Breaking chemical product patent protection, achieving parallel importation or making generic drugs enter into the China's market, can save huge amount of medicines procurement budget for the government, and benefit the general public. Conclusion Developing and implementing medicines registration and intellectual property right protection strategies with public health perspective, adding continuously improved basic health insurance programs, can effectively promote the affordability of high cost medicines with significant public health, social, political and economic implications.

Citation： SUNJing, ZHAOHong-yan, MALi-ping, DONGSi-ping, YANGTing-ting, YokeLing, PaulCowthrone, CHENXi-ping, CHENYou-ding. Affordability of High Cost Medicines with Significant Public Health Implications under Medicines Patent Protection System in China. Chinese Journal of Evidence-Based Medicine, 2014, 14(5): 509-516. doi: 10.7507/1672-2531.20140088 Copy

1.	《关于深化医药卫生体制改革的意见》.中共中央国务院, 2009. Available at: http://www.gov.cn/jrzg/2009-04/06/content_1278721.htm.
2.	Pan American Health Organization. Access to High-Cost Medicines in the Americas:Situation, Challenges and Perspective. Area of Technology, Health Care and Research, Essential Medicines and Biologicals Unit (THR/EM). Washington DC. 2010.
3.	卫生部统计信息中心.第四次卫生服务调查专题研究报告(一)中国基层卫生服务研究.北京:中国协和医科大学出版社. 2009.
4.	卫生部卫生统计信息中心. 2011年卫生统计年鉴.卫生部. 2011.
5.	World Health Organization. Death and DALY country estimates 2004. Available at: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls.
6.	中华医学会心血管病学分会、中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2010年版).中华心血管病杂志, 2010, 38(8):675-690.
7.	中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011非小细胞肺癌临床实践指南(NCCN中国版). Available at:http://guide.medlive.cn/guideline/1842.
8.	中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011胃癌临床实践指南(NCCN中国版). Available at: http://guide.medlive.cn/guideline/497.
9.	中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011乳腺癌临床实践指南(NCCN中国版). Available at: http://guide.medlive.cn/guideline/1667.
10.	中华医学会血液学分会.中国慢性髓系性白血病诊断与治疗指南(2011年版).中国血液学杂志, 2011, 32(6):426-432.
11.	中国疾病预防控制中心.国家免费艾滋病抗病毒药物治疗手册(2012年版). Available at: http://chinaaids.cn/n16/n1133/n827769.files/n827768.pdf.
12.	中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中国预防医学杂志, 2011, 12(1):1-15.
13.	慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识.中华实验和临床感染病杂志, 2009, 8(3):343-352.
14.	中华人民共和国国家统计局, 中国统计年鉴2011. Available at: http://www.stats.gov.cn/tjsj/ndsj/2011/indexch.htm.
15.	World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components (2nd Edition). WHO & HAI Working Document. WHO/PSM/ PAR/2008.3. Geneva. 2008.
16.	中国疾病预防控制中心. 2009年两会特刊-慢性病防治专辑.中国新闻社. 2009.
17.	中国疾病预防控制中心. 2012年中国艾滋病调查报告.中国疾病预防控制中心. 2012.
18.	中国疾病预防控制中心. 2006年全国人群乙型肝炎等有关疾病血清流行病学调查结果. Available at: http://www.chinacdc.cn/n272442/n272530/n3246177/23316.html.
19.	中国疾病预防控制中心.中国约有3800万丙型肝炎患者尚无疫苗可预防. Available at: http://www.chinacdc.cn/mtdx/crbxx/201005/t20100514_38199.htm.
20.	中华医学会血液学分会.中国慢性髓系性白血病诊断与治疗指南(2011年版).中国血液学杂志, 2011, 32(6):426-432.
21.	刘宇飞.晚期或转移性非小细胞肺癌的一线化疗.实用临床医药杂志, 2009, 13(4):27-30.
22.	代敏, 任建松, 李霓等.中国2008年肿瘤发病和死亡情况估计及预测.中华流行病学杂志, 2012, 33(1):57-61.
23.	卫生部卫生发展研究中心.中国卫生总费用报告.北京. 2011.
24.	Management Science for Health. International Drug Price Indicator Guide 2011. Cambridge, MA, US. Available at: http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=English.
25.	晋灿瑞, 刘霞, 马春涛, 等.我国艾滋病抗病毒治疗药品费用分析.中华预防医学杂志, 2012, 46(9):862-863.
26.	新华网.新华调查:"水货药"陷道德与法律困境. Available at: http://www.lijiannet.com/nav.php?id=259468&page=3.

1. 《关于深化医药卫生体制改革的意见》.中共中央国务院, 2009. Available at: http://www.gov.cn/jrzg/2009-04/06/content_1278721.htm.
2. Pan American Health Organization. Access to High-Cost Medicines in the Americas:Situation, Challenges and Perspective. Area of Technology, Health Care and Research, Essential Medicines and Biologicals Unit (THR/EM). Washington DC. 2010.
3. 卫生部统计信息中心.第四次卫生服务调查专题研究报告(一)中国基层卫生服务研究.北京:中国协和医科大学出版社. 2009.
4. 卫生部卫生统计信息中心. 2011年卫生统计年鉴.卫生部. 2011.
5. World Health Organization. Death and DALY country estimates 2004. Available at: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls.
6. 中华医学会心血管病学分会、中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2010年版).中华心血管病杂志, 2010, 38(8):675-690.
7. 中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011非小细胞肺癌临床实践指南(NCCN中国版). Available at:http://guide.medlive.cn/guideline/1842.
8. 中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011胃癌临床实践指南(NCCN中国版). Available at: http://guide.medlive.cn/guideline/497.
9. 中国抗癌协会临床肿瘤学协作专业委员会(CSCO, Chinese Society of Clinical Oncology). 2011乳腺癌临床实践指南(NCCN中国版). Available at: http://guide.medlive.cn/guideline/1667.
10. 中华医学会血液学分会.中国慢性髓系性白血病诊断与治疗指南(2011年版).中国血液学杂志, 2011, 32(6):426-432.
11. 中国疾病预防控制中心.国家免费艾滋病抗病毒药物治疗手册(2012年版). Available at: http://chinaaids.cn/n16/n1133/n827769.files/n827768.pdf.
12. 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中国预防医学杂志, 2011, 12(1):1-15.
13. 慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识.中华实验和临床感染病杂志, 2009, 8(3):343-352.
14. 中华人民共和国国家统计局, 中国统计年鉴2011. Available at: http://www.stats.gov.cn/tjsj/ndsj/2011/indexch.htm.
15. World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components (2nd Edition). WHO & HAI Working Document. WHO/PSM/ PAR/2008.3. Geneva. 2008.
16. 中国疾病预防控制中心. 2009年两会特刊-慢性病防治专辑.中国新闻社. 2009.
17. 中国疾病预防控制中心. 2012年中国艾滋病调查报告.中国疾病预防控制中心. 2012.
18. 中国疾病预防控制中心. 2006年全国人群乙型肝炎等有关疾病血清流行病学调查结果. Available at: http://www.chinacdc.cn/n272442/n272530/n3246177/23316.html.
19. 中国疾病预防控制中心.中国约有3800万丙型肝炎患者尚无疫苗可预防. Available at: http://www.chinacdc.cn/mtdx/crbxx/201005/t20100514_38199.htm.
20. 中华医学会血液学分会.中国慢性髓系性白血病诊断与治疗指南(2011年版).中国血液学杂志, 2011, 32(6):426-432.
21. 刘宇飞.晚期或转移性非小细胞肺癌的一线化疗.实用临床医药杂志, 2009, 13(4):27-30.
22. 代敏, 任建松, 李霓等.中国2008年肿瘤发病和死亡情况估计及预测.中华流行病学杂志, 2012, 33(1):57-61.
23. 卫生部卫生发展研究中心.中国卫生总费用报告.北京. 2011.
24. Management Science for Health. International Drug Price Indicator Guide 2011. Cambridge, MA, US. Available at: http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=English.
25. 晋灿瑞, 刘霞, 马春涛, 等.我国艾滋病抗病毒治疗药品费用分析.中华预防医学杂志, 2012, 46(9):862-863.
26. 新华网.新华调查:"水货药"陷道德与法律困境. Available at: http://www.lijiannet.com/nav.php?id=259468&page=3.

Chinese Journal of Evidence-Based Medicine

Affordability of High Cost Medicines with Significant Public Health Implications under Medicines Patent Protection System in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content